HAC (Russian)
RSCI (Russian)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Prevalence, risk factors, and diagnosis of comorbidity of chronic obstructive pulmonary disease and cardiovascular disease

DOI: https://doi.org/10.29296/25877305-2020-09-05
Download full text PDF

A. Chaulin(1, 2); I. Milyutin(2, 3); Professor D. Duplyakov(1, 2), MD (1)Samara Regional
Cardiology Dispensary (2)Samara State Medical University (3)Samara City N.I. Pirogov Clinical Hospital №1

At present, doctors with various medical specialties are often found with comorbidity (a combination of several diseases in the same patient). An important place among them is occupied by the problem of the combination of chronic obstructive pulmonary disease and cardiovascular diseases, due to the fact that these diseases affect the vital systems of the body, are widespread, have almost the same risk factors for occurrence, and there is still no consensus on the optimal diagnosis and treatment of such patients. This article presents current data on the prevalence, risk factors, pathogenesis and diagnosis of comorbidity of chronic obstructive pulmonary disease and cardiovascular disease.

chronic obstructive pulmonary disease
cardiovascular disease
heart failure
myocardial infarction
risk factors

It appears your Web browser is not configured to display PDF files. Download adobe Acrobat или click here to download the PDF file.

  1. Feinstein A.R. The pre-therapeutic classification of comorbidity in chronic disease. J Chronic Dis. 1970; 23 (7): 455–68. DOI: 10.1016/0021-9681(70)90054-8
  2. Vertkin A.L. Komorbidnost': istorija, sovremennoe predstavlenie, profilaktika i lechenie. Kardiovaskuljarnaja terapija i profilaktika. 2015; 14 (2): 74–9 [Vertkin A.L. Comorbidity: history, recent views, prevention and treatment. Cardiovascular Therapy and Prevention. 2015; 14 (2): 74–9 (in Russ.)]. https://doi.org/10.15829/1728-8800-2015-2-74-79
  3. Charlson M.E., Pompei P., Ales K.L. et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987; 40 (5): 373–83. DOI: 10.1016/0021-9681(87)90171-8
  4. Tarlovskaja E.I. Komorbidnost' i polimorbidnost' – sovremennaja traktovka i nasuschnye zadachi, stojaschie pered terapevticheskim soobschestvom. Kardiologija. 2018; 58 (S9): 29–38 [Tarlovskaya E.I. Comorbidity and polymorbidity – a modern interpretation and urgent tasks facing the therapeutic community. Kardiologiia. 2018; 58 (9S): 29–38 (in Russ.)]. DOI: 10.18087/cardio.2562
  5. Adeloye D., Chua S., Lee C. et al. Global and regional estimates of COPD prevalence: Systematic review and meta-analysis. J Glob Health. 2015; 5 (2): 020415. DOI: 10.7189/jogh.05-020415
  6. Public Health England. Public Health Profiles: Inhale – INteractive Health Atlas of Lung conditions in England. London: Public Health England. URL: http://fingertips.phe.org.uk/
  7. GBD 2015 Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med. 2017; 5 (9): 691–706. DOI: 10.1016/S2213-2600(17)30293-X
  8. Divo M., Cote C., de Torres J.P. et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 186 (2): 155–61. DOI: 10.1164/rccm.201201-0034OC
  9. Chen W., Thomas J., Sadatsafavi M. et al. Risk of cardiovascular comorbidity in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med. 2015; 3 (8): 631–9. DOI: 10.1016/S2213-2600(15)00241-6
  10. Cazzola M., Rogliani P., Matera M.G. Cardiovascular disease in patients with COPD. Lancet Respir Med. 2015; 3 (8): 593–5. DOI: 10.1016/S2213-2600(15)00279-9
  11. Roversi S., Fabbri L.M., Sin D.D. et al. Chronic Obstructive Pulmonary Disease and Cardiac Diseases. An Urgent Need for Integrated Care. Am J Respir Crit Care Med. 2016; 194 (11): 1319–36. DOI: 10.1164/rccm.201604-0690SO
  12. Mullerova H., Agusti A., Erqou S. et al. Cardiovascular comorbidity in COPD: systematic literature review. Chest. 2013; 144 (4): 1163–78. DOI: 10.1378/chest.12-2847
  13. Grigor'eva N.Ju., Majorova M.V., Koroleva M.E. i dr. Osobennosti formirovanija i razvitija serdechno-sosudistyh zabolevanij u bol'nyh hronicheskoj obstruktivnoj bolezn'ju legkih. Ter arh. 2019; 91 (1): 16–47 [Grigoryeva N.Yu., Maiorova M.V., Korolyova M.E. et al. Somorbidity and polymorbidity of the patient with chronic obstructive pulmonary disease and cardiovascular diseases. Therapeutic Archive. 2019; 91 (1): 16–47 (in Russ.)]. DOI: 10.26442/00403660.2019.01.000027
  14. Lahousse L., Tiemeier H., Ikram M.A. et al. Chronic obstructive pulmonary disease and cerebrovascular disease: A comprehensive review. Respir Med. 2015; 109 (11): 1371–80. DOI: 10.1016/j.rmed.2015.07.014
  15. Morgan A.D., Sharma C., Rothnie K.J et al. Chronic Obstructive Pulmonary Disease and the Risk of Stroke. Ann Am Thorac Soc. 2017; 14 (5): 754–65. DOI: 10.1513/AnnalsATS.201611-932SR
  16. Houben-Wilke S., Jorres R.A, Bals R. et al. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study. Am J Respir Crit Care Med. 2017; 195 (2): 189–97. DOI: 10.1164/rccm.201602-0354OC
  17. Brusselle G., Bracke K., De Pauw M. Peripheral Artery Disease in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med. 2017; 195 (2): 148–50. DOI: 10.1164/rccm.201608-1712ED
  18. Decramer M., Janssens W. Chronic obstructive pulmonary disease and comorbidities. Lancet Respir Med. 2013; 1 (1): 73–83. DOI: 10.1016/S2213-2600(12)70060-7
  19. Maclay J.D., MacNee W. Cardiovascular disease in COPD: mechanisms. Chest. 2013; 143 (3): 798–807. DOI: 10.1378/chest.12-0938
  20. Fabbri L.M. Smoking, Not COPD, as the Disease. N Engl J Med. 2016; 374 (19): 1885–6. DOI: 10.1056/NEJMe1515508
  21. Rabe K.F., Watz H. Chronic obstructive pulmonary disease. Lancet. 2017; 389 (10082): 1931–40. DOI: 10.1016/S0140-6736(17)31222-9
  22. Belenkov Ju.N., Tsvetkova O.A., Privalova E.V. i dr. Komorbidnost' hronicheskoj obstruktivnoj bolezni legkih i serdechno-sosudistyh zabolevanij: mesto terapii sovremennymi β-adrenoblokatorami. Kardiologija. 2019; 59 (6): 48–55 [Belenkov Y.N., Tsvetkova O.A., Privalova E.V. et al. Comorbidity of Chronic Obstructive Pulmonary Disease and Cardiovascular Diseases: Place of Therapy with Modern β-Adrenoblockers. Kardiologiia. 2019; 59 (6): 48–55 (in Russ.)]. https://doi.org/10.18087/cardio.2019.6.n458
  23. Agafonova O.V., Gritsenko T.A., Bogdanova Ju.V. i dr. Poliklinicheskaja terapija: Uchebnik. Pod red. D.I. Davydkina, Ju.V. Schukina. 2-e izd., pererab. i dop. M.: GEOTAR-Media, 2020; 840 s. [Agafonova O.V., Gritsenko T.A., Bogdanova Yu.V. i dr. Poliklinicheskaya terapiya: Uchebnik. Pod red. D.I. Davydkina, Yu.V. Shchukina. 2-e izd., pererab. i dop. M.: GEOTAR-Media, 2020; 840 s. (in Russ.)]. DOI: 10.33029/9704-5545-6-PLT-2020-1-840
  24. Violan C., Foguet-Boreu Q., Flores-Mateo G. et al. Prevalence, determinants and patterns of multimorbidity in primary care: a systematic review of observational studies. PLoS One. 2014; 9 (7): e102149. DOI: 10.1371/journal.pone.0102149
  25. Barnes P.J. Senescence in COPD and Its Comorbidities. Annu Rev Physiol. 2017; 79: 517–39. DOI: 10.1146/annurev-physiol-022516-034314
  26. Savale L., Chaouat A., Bastuji-Garin S. et al. Shortened telomeres in circulating leukocytes of patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009; 179 (7): 566–71. DOI: 10.1164/rccm.200809-1398OC
  27. Tsuji T., Aoshiba K., Nagai A. Alveolar cell senescence in patients with pulmonary emphysema. Am J Respir Crit Care Med. 2006; 174 (8): 886–93. DOI: 10.1164/rccm.200509-1374OC
  28. Benetos A., Okuda K., Lajemi M. et al. Telomere length as an indicator of biological aging: the gender effect and relation with pulse pressure and pulse wave velocity. Hypertension. 2001; 37 (2 Pt 2): 381–5. DOI: 10.1161/01.hyp.37.2.381
  29. Maclay J.D., McAllister D.A., Rabinovich R. et al. Systemic elastin degradation in chronic obstructive pulmonary disease. Thorax. 2012; 67 (7): 606–12. DOI: 10.1136/thoraxjnl-2011-200949
  30. Austin V., Crack P.J., Bozinovski S. et al. COPD and stroke: are systemic inflammation and oxidative stress the missing links? Clin Sci (Lond). 2016; 130 (13): 1039–50. DOI: 10.1042/CS20160043
  31. Kida Y., Goligorsky M.S. Sirtuins, Cell Senescence, and Vascular Aging. Can J Cardiol. 2016; 32 (5): 634–41. DOI: 10.1016/j.cjca.2015.11.022
  32. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. Circulation. 2002; 105 (9): 1135–43. DOI: 10.1161/hc0902.104353
  33. Gan W.Q., Man S.F., Senthilselvan A. et al. Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis. Thorax. 2004; 59 (7): 574–80. DOI: 10.1136/thx.2003.019588
  34. de Torres J.P., Cordoba-Lanus E., Lopez-Aguilar C. et al. C-reactive protein levels and clinically important predictive outcomes in stable COPD patients. Eur Respir J. 2006; 27 (5): 902–7. DOI: 10.1183/09031936.06.00109605
  35. Hurst J.R., Donaldson G.C., Perera W.R. et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2006; 174 (8): 867–74. DOI: 10.1164/rccm.200604-506OC
  36. Roversi S., Roversi P., Spadafora G. et al. Coronary artery disease concomitant with chronic obstructive pulmonary disease. Eur J Clin Invest. 2014; 44 (1): 93–102. DOI: 10.1111/eci.12181
  37. Celli B.R., Locantore N., Yates J. et al. Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2012; 185 (10): 1065–72. DOI: 10.1164/rccm.201110-1792OC
  38. Marchetti N., Ciccolella D.E., Jacobs M.R. et al. Hospitalized acute exacerbation of COPD impairs flow and nitroglycerin-mediated peripheral vascular dilation. COPD. 2011; 8 (2): 60–5. DOI: 10.3109/15412555.2011.558541
  39. Seidel D., Cheung A., Suh E.S. et al. Physical inactivity and risk of hospitalisation for chronic obstructive pulmonary disease. Int J Tuberc Lung Dis. 2012; 16 (8): 1015–9. DOI: 10.5588/ijtld.12.0050
  40. Cohen A.J., Brauer M., Burnett R. et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the Global Burden of Diseases Study 2015. Lancet. 2017; 389 (10082): 1907–18. DOI: 10.1016/S0140-6736(17)30505-6
  41. Wright J.L., Petty T., Thurlbeck W.M. Analysis of the structure of the muscular pulmonary arteries in patients with pulmonary hypertension and COPD: National Institutes of Health nocturnal oxygen therapy trial. Lung. 1992; 170 (2): 109–24. DOI: 10.1007/bf00175982
  42. Dinh-Xuan A.T., Higenbottam T.W., Clelland C.A. et al. Impairment of endothelium-dependent pulmonary-artery relaxation in chronic obstructive lung disease. N Engl J Med. 1991; 324 (22): 1539–47. DOI: 10.1056/NEJM199105303242203
  43. Chaudary N., Geraci S.A. Prognostic value of cardiac-specific troponins in chronic obstructive pulmonary disease exacerbations: a systematic review. J Miss State Med Assoc. 2014; 55 (2): 40–4. URL: https://www.ncbi.nlm.nih.gov/pubmed/25771612
  44. Chaulin A.M., Karsljan L.S., Grigor'eva E.V. i dr. Kliniko-diagnosticheskaja tsennost' kardiomarkerov v biologicheskih zhidkostjah cheloveka. Kardiologija. 2019; 59 (11): 66–75 [Chaulin A.M., Karslyan L.S., Bazyuk E.V. et al. Clinical and Diagnostic Value of Cardiac Markers in Human Biological Fluids. Kardiologiia. 2019; 59 (11): 66–75 (in Russ.)]. https://doi.org/10.18087/cardio.2019.11.n414
  45. Chaulin A.M., Karsljan L.S., Grigor'eva E.V. i dr. Osobennosti metabolizma serdechnyh troponinov (obzor literatury). Kompleksnye problemy serdechno-sosudistyh zabolevanij. 2019; 8 (4): 103–15 [Chaulin A.M., Karslyan L.S., Grigorieva E.V. et al. Metabolism of cardiac troponins (literature review). Complex Issues of Cardiovascular Diseases. 2019; 8 (4): 103–15 (in Russ.)]. https://doi.org/10.17802/2306-1278-2019-8-4-103-115
  46. Chaulin A.M., Karsljan L.S., Dupljakov D.V. Nekoronarogennye prichiny povyshenija troponinov v klinicheskoj praktike. Klinicheskaja praktika. 2019; 10 (4): 81–93 [Chaulin A.M., Karslyan L.S., Duplyakov D.V. Non-coronarogenic causes of increased cardiac troponins in clinical practice. Journal of Clinical Practice. 2019; 10 (4): 81–93 (in Russ.)]. https://doi.org/10.17816/clinpract16309
  47. Chaulin A.M., Dupljakov D.V. Povyshenie kardial'nyh troponinov, ne assotsiirovannoe s ostrym koronarnym sindromom. Chast' 1. Kardiologija: novosti, mnenija, obuchenie. 2019; 7 (2): 13–23 [Chaulin A.M., Duplyakov D.V. Increased cardiac troponins, not associated with acute coronary syndrome. Part 1. Kardiologiya: novosti, mneniya, obuchenie = Cardiology: News, Opinions, Training. 2019; 7 (2): 13–23 (in Russ.)]. DOI: 10.24411/2309-1908-2019-12002
  48. Lahousse L., Verhamme K.M., Stricker B.H. et al. Cardiac effects of current treatments of chronic obstructive pulmonary disease. Lancet Respir Med. 2016; 4 (2): 149–64. DOI: 10.1016/S2213-2600(15)00518-4
  49. Gershon A., Croxford R., Calzavara A. et al. Cardiovascular safety of inhaled long-acting bronchodilators in individuals with chronic obstructive pulmonary disease. JAMA Intern Med. 2013; 173 (13): 1175–85. DOI: 10.1001/jamainternmed.2013.1016
  50. Rothnie K.J., Smeeth L., Herrett E. et al. Closing the mortality gap after a myocardial infarction in people with and without chronic obstructive pulmonary disease. Heart. 2015; 101 (14): 1103–10. DOI: 10.1136/heartjnl-2014-307251
  51. Lipworth B., Wedzicha J., Devereux G. et al. Beta-blockers in COPD: time for reappraisal. Eur Respir J. 2016; 48 (3): 880–8. DOI: 10.1183/13993003.01847-2015
  52. Vanfleteren L.E., Spruit M.A., Wouters E.F. et al. Management of chronic obstructive pulmonary disease beyond the lungs. Lancet Respir Med. 2016; 4 (11): 911–24. DOI: 10.1016/S2213-2600(16)00097-7
  53. MacDonald M.I., Shafuddin E., King P.T. et al. Cardiac dysfunction during exacerbations of chronic obstructive pulmonary disease. Lancet Respir Med. 2016; 4 (2): 138–48. DOI: 10.1016/S2213-2600(15)00509-3